Literature DB >> 12707034

Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.

Riichiro Abe1, Tadamichi Shimizu, Akihiko Shibaki, Hideki Nakamura, Hirokazu Watanabe, Hiroshi Shimizu.   

Abstract

The pathogeneses of toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS), both severe blistering diseases usually associated with drug intake, are not fully elucidated. Histologically, both TEN and SJS are characterized by extensive keratinocyte apoptosis. Previous studies have shown that keratinocyte apoptosis in TEN and SJS was induced by a suicidal interaction between Fas and Fas ligand (FasL), which are both expressed by keratinocytes. However, our preliminary examinations demonstrated that FasL is hardly detected on keratinocytes. We hypothesized that soluble FasL (sFasL) is secreted by peripheral blood mononuclear cells (PBMCs), and this interacts with the Fas expressed on keratinocytes in TEN and SJS. To justify this hypothesis, we investigated whether sFasL secreted by PBMCs could induce the keratinocyte apoptosis in TEN and SJS. Enzyme-linked immunosorbent assay analysis demonstrated that there was no significant sFasL increase in any samples of healthy controls (<40 pg/ml, n = 14) and patients with an ordinary erythema multiforme-type drug eruption (41.5 +/- 3.1 pg/ml, n = 14), whereas high concentrations are detected in all samples of TEN and SJS patients (TEN: 131.5 +/- 57.4 pg/ml, n = 8; SJS: 119.1 +/- 41.0 pg/ml, n = 14) (P < 0.0001). In vitro analysis using cultured keratinocytes revealed that the sera of TEN and SJS patients induced abundant keratinocyte apoptosis compared to erythema multiforme-type drug eruption sera. Furthermore, on stimulation with the causal drug, PBMCs obtained from TEN and SJS patients secreted high levels of sFasL. Taken together, these results indicate that sFasL secreted by PBMCs, not keratinocytes, plays a crucial role in the apoptosis and pathomechanism of TEN and SJS, and that the serum sFasL level may be a good indicator for the early diagnosis of TEN and SJS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707034      PMCID: PMC1851208          DOI: 10.1016/S0002-9440(10)64284-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.

Authors:  M Fischer; E Fiedler; W C Marsch; J Wohlrab
Journal:  Br J Dermatol       Date:  2002-04       Impact factor: 9.302

2.  Toxic epidermal necrolysis treated with cyclosporin.

Authors:  J Hewitt; A D Ormerod
Journal:  Clin Exp Dermatol       Date:  1992-07       Impact factor: 3.470

3.  Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  L H Lerner; A A Qureshi; B V Reddy; E A Lerner
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

4.  Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

Authors:  Amal Nassif; Armand Bensussan; Guillaume Dorothée; Fathia Mami-Chouaib; Nicolas Bachot; Martine Bagot; Laurence Boumsell; Jean-Claude Roujeau
Journal:  J Invest Dermatol       Date:  2002-04       Impact factor: 8.551

5.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

Review 6.  Death receptors in cutaneous biology and disease.

Authors:  P Wehrli; I Viard; R Bullani; J Tschopp; L E French
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

7.  Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid "pulse therapy".

Authors:  E F Sherertz; B V Jegasothy; G S Lazarus
Journal:  J Am Acad Dermatol       Date:  1985-01       Impact factor: 11.527

8.  Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.

Authors:  P Wolkenstein; J Latarjet; J C Roujeau; C Duguet; S Boudeau; L Vaillant; M Maignan; M H Schuhmacher; B Milpied; A Pilorget; H Bocquet; C Brun-Buisson; J Revuz
Journal:  Lancet       Date:  1998-11-14       Impact factor: 79.321

9.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01

10.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  39 in total

Review 1.  Keratinocyte apoptosis in epidermal development and disease.

Authors:  Deepak Raj; Douglas E Brash; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2006-02       Impact factor: 8.551

2.  FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major.

Authors:  Liv Eidsmo; Caroline Fluur; Bence Rethi; Sofia Eriksson Ygberg; Nicolas Ruffin; Angelo De Milito; Hannah Akuffo; Francesca Chiodi
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

Authors:  Lois La Grenade; Lauren Lee; Joyce Weaver; Renan Bonnel; Claudia Karwoski; Laura Governale; Allen Brinker
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Don't live in a town where there are no doctors: toxic epidermal necrolysis initially misdiagnosed as oral thrush.

Authors:  Abdul Majid Wani; Waleed Mohd Hussain; Mohamad Ibrahim Fatani; Khaled Shawkat Ali; Amer Mohd Khoujah; Mubeena Akhtar; Ghassan Adnan Al Maimani; Sadeya Hanif Raja; Ashraf Basraheel; Khurram Fareed
Journal:  BMJ Case Rep       Date:  2009-12-30

5.  The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis.

Authors:  Liv Eidsmo; Susanne Nylen; Ali Khamesipour; Mari-Anne Hedblad; Francesca Chiodi; Hannah Akuffo
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

6.  Proapoptotic CD95L levels in normal human serum and sera of breast cancer patients.

Authors:  Vicente Olimón-Andalón; Adriana Aguilar-Lemarroy; Sarah Ratkovich-González; Aida Uribe-López; Ignacio Mariscal-Ramírez; Raúl Delgadillo-Cristerna; Pablo Ortiz-Lazareno; Georgina Hernández-Flores; Ruth de Celis; Alejandro Bravo-Cuellar; Luis F Jave-Suárez
Journal:  Tumour Biol       Date:  2015-01-04

7.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

8.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Lieh-Bang Liou; Chen-Chung Chu; Marie Lin; Hsien-Ping Huang; Yen-Ling Lin; Joung-Liang Lan; Li-Cheng Yang; Hong-Shang Hong; Ming-Jing Chen; Ping-Chin Lai; Mai-Szu Wu; Chia-Yu Chu; Kuo-Hsien Wang; Chien-Hsiun Chen; Cathy S J Fann; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-02       Impact factor: 11.205

9.  Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

Authors:  Sho-ichi Yamagishi; Riichiro Abe; Yosuke Inagaki; Kazuo Nakamura; Hiroshi Sugawara; Daisuke Inokuma; Hideki Nakamura; Tadamichi Shimizu; Masayoshi Takeuchi; Akihiko Yoshimura; Richard Bucala; Hiroshi Shimizu; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  HIV Tat potentiates cell toxicity in a T cell model for sulphamethoxazole-induced adverse drug reactions.

Authors:  Kemi Adeyanju; Adriana Krizova; Philippe A Gilbert; Gregory A Dekaban; Michael Rieder
Journal:  Virus Genes       Date:  2009-03-10       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.